Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III study of SPK-8011 for hemophilia A

Trial Profile

A Phase III study of SPK-8011 for hemophilia A

Planning
Phase of Trial: Phase III

Latest Information Update: 02 Dec 2018

At a glance

  • Drugs SPK 8011 (Primary)
  • Indications Haemophilia A
  • Focus Therapeutic Use
  • Sponsors Spark Therapeutics
  • Most Recent Events

    • 02 Dec 2018 According to a Spark Therapeutics media release, the company intends to initiate this phase 3 run-in study by the end of 2018 to collect prospective observational data on trial participants.
    • 20 Aug 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top